BCKDK DNA is amplified in 15.21% tumors of ovarian cancer patients, which is the second highest proportion just lower than that of uterine carcinosarcomas of 17.86% (Figure 1(f)). This evidence concerns the gene BCKDK and uterine carcinosarcoma.